Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone
administration in subjects with Opioid-induced Bowel Dysfunction.
Phase:
Phase 3
Details
Lead Sponsor:
Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc.